Novoste CEO’s Challenge: Stabilize Brachy Biz Or Ink Merger While Cash Lasts
This article was originally published in The Gray Sheet
Executive Summary
Novoste's cash burn rate of about $1 mil. per month puts pressure on management either to acquire a growth platform to augment flagging Beta-Cath vascular brachytherapy revenue or sell the company
You may also be interested in...
Novoste To Merge With ONI Medical, Exits Once-Promising Brachy Biz
Novoste will attempt to divest its Beta-Cath vascular brachytherapy (VBT) business to one of several interested parties prior to the firm's merger with ONI Medical, likely to close in the third quarter
Novoste To Merge With ONI Medical, Exits Once-Promising Brachy Biz
Novoste will attempt to divest its Beta-Cath vascular brachytherapy (VBT) business to one of several interested parties prior to the firm's merger with ONI Medical, likely to close in the third quarter
Digene Stock Rebound Could Continue In 2005; OTC Index Ahead 23%
Digene's increased focus on physician detailing for its DNAwithPap human papillomavirus test, coupled with plans for consumer advertising, could allow the firm to exceed recently revised growth expectations